Lipoatrophy, Lipodystrophy, and Insulin Resistance
Authors: Om P. Ganda
Journal: Annals of Internal Medicine (2000)

Editorials15 August 2000Lipoatrophy, Lipodystrophy, and Insulin ResistanceOm P. Ganda, MDOm P. Ganda, MDJoslin Diabetes Center; Boston, MA 02215 (Ganda)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-4-200008150-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In 1946, R.D. Lawrence described the characteristics of lipoatrophic diabetes, an unusual constellation of generalized absence of adipose tissue, insulin-resistant diabetes mellitus, absence of ketosis, marked lipemia with hepatomegaly, and elevated basal metabolic rate (1). More than 100 cases with similar features have been reported in the literature thus far (2, 3). Although the syndrome is rare, its true prevalence in unknown because of the heterogeneity of clinical features in individual patients.The absence of adipose tissue, initially considered to be a sine qua non, does not affect all parts of the body in many patients (hence the term lipodystrophy), ...References1. Lawrence RD. Lipodystrophy and hepatomegaly with diabetes, lipemia and other metabolic disturbances: a case throwing new light on the action of insulin. Lancet. 1946;1:724-31. CrossrefMedlineGoogle Scholar2. Rossini AA. Lipoatrophic diabetes. In: Marble A, Krall LP, Bradley RF, Christlieb AR, Soeldner JS, eds. Joslin's Diabetes Mellitus. 12th ed. Philadelphia: Lea & Febiger; 1985:834-42. Google Scholar3. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl. 1996;413:2-28. CrossrefMedlineGoogle Scholar4. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J. Troglitazone action is independent of adipose tissue. J Clin Invest. 1997;100:2900-8. CrossrefMedlineGoogle Scholar5. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, et al . Life without white fat: a transgenic mouse. Genes Dev. 1998;12:3168-81. CrossrefMedlineGoogle Scholar6. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, et al . Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 1998;12:3182-94. CrossrefMedlineGoogle Scholar7. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, et al . Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest. 2000;105:271-8. CrossrefMedlineGoogle Scholar8. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin-resistance and type II diabetes. Diabetes. 1996;45:1661-9. CrossrefMedlineGoogle Scholar9. Scheen AJ, Lefebvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care. 1999;22:1568-77. CrossrefMedlineGoogle Scholar10. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al . Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133:263-74. LinkGoogle Scholar11. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes. 2000;49:883-8. CrossrefMedlineGoogle Scholar12. Barzilai N, She L, Liu BQ, Vuguin P, Cohen P, Wang J, et al . Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes. 1999;48:94-8. CrossrefMedlineGoogle Scholar13. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 1999;22:288-93. CrossrefMedlineGoogle Scholar14. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, et al . Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999;22:908-12. CrossrefMedlineGoogle Scholar15. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance. A reexamination. Diabetes. 2000;49:677-83. CrossrefMedlineGoogle Scholar16. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-9. CrossrefMedlineGoogle Scholar17. Yanovski JA, Miller KD, Kino T, Friedman TC, Chrousos GP, Tsigos C, et al . Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab. 1999;84:1925-31. CrossrefMedlineGoogle Scholar18. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab. 2000;85:35-41. MedlineGoogle Scholar19. Persighen G, Meneghini E, Scifo P, Pagliato E, Mignogna G, Tambussi G, et al . Intramyocellular triglyceride content is increased in HIV-1 patients with peripheral lipodystrophy [Abstract]. Diabetes. 2000;49 Suppl 1 A71. Google Scholar20. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities [Letter]. Lancet. 1998;352:1031-2. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Om P. Ganda, MDAffiliations: Joslin Diabetes Center; Boston, MA 02215 (Ganda)Grant Support: In part by National Center for Research Resources–National Institutes of Health grant 2 MO1-RR001032-25 to the Beth Israel Deaconess Medical Center, General Clinical Research Center.Corresponding Author: Om P. Ganda, MD, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215; e-mail, om.ganda@joslin.harvard.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEfficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes Elif Arioglu , Jennifer Duncan-Morin , Nancy Sebring , Kristina I. Rother , Nicole Gottlieb , Jay Lieberman , David Herion , David E. Kleiner , James Reynolds , Ahalya Premkumar , Anne E. Sumner , Jay Hoofnagle , Marc L. Reitman , and Simeon I. Taylor Metrics Cited byDeletion of Seipin Attenuates Vascular Function and the Anticontractile Effect of Perivascular Adipose TissueAdipose tissue metabolism and inflammation in obesityMeta- and cross-species analyses of insulin resistance based on gene expression datasets in human white adipose tissuesThe Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue FunctionUpregulation of Pnpla2 and Abhd5 and downregulation of G0s2 gene expression in mesenteric white adipose tissue as a potential reason for elevated concentration of circulating NEFA after removal of retroperitoneal, epididymal, and inguinal adipose tissueIn anorexia nervosa, even a small increase in abdominal fat is responsible for the appearance of insulin resistanceThe role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated reviewInhibition of the chemokine (C–C motif) ligand 2/chemokine (C–C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophyObesity and diabetes: lipids, ‘nowhere to run to'Lipodystrophy SyndromesThe role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistanceCaloric restriction and refeeding promoted different metabolic effects in fat depots and impaired dyslipidemic profile in ratsInvolvement of the renin-angiotensin system in obesity: Older and newer pathwaysCoculture with Primary Visceral Rat Adipocytes from Control But Not Streptozotocin-Induced Diabetic Animals Increases Glucose Uptake in Rat Skeletal Muscle Cells: Role of AdiponectinEndothelial Function Varies According to Insulin Resistance Disease TypePlace du tissu adipeux dans la physiopathologie du diabète de type 2Lipohypertrophy—a complication of insulin injectionsLipohypertrophy—a complication of insulin injectionsLipodystrophy Syndrome: The Morphologic and Metabolic Effects of Antiretroviral Therapy in HIV InfectionRole of the Adipocyte in Type 2 DiabetesLipodystrophy, Insulin Resistance, Diabetes Mellitus, Dyslipidemia, and Cardiovascular Disease in Human Immunodeficiency Virus InfectionACRP30/adiponectin: an adipokine regulating glucose and lipid metabolismInhibition of cAMP-response Element-binding Protein Activity Decreases Protein Kinase B/Akt Expression in 3T3-L1 Adipocytes and Induces ApoptosisSynergistic Antiadipogenic Effects of HIV Type 1 Protease Inhibitors with Tumor Necrosis Factor α : Suppression of Extracellular Insulin Action Mediated by Extracellular Matrix-Degrading ProteasesThe adipocyte-secreted protein Acrp30 enhances hepatic insulin actionAdipose tissue and the insulin resistance syndrome 15 August 2000Volume 133, Issue 4Page: 304-306KeywordsAdipocytesAdipose tissueFatsInsulinInsulin resistanceLipidsLipodystrophyProtease inhibitorsTransplantationType 2 diabetes ePublished: 15 August 2000 Issue Published: 15 August 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...